DICOVAL ER 250
Stable Release. Precision Control.
Overview
DICOVAL ER 250 is a specialized Extended-Release (ER) formulation of Divalproex Sodium, meticulously engineered for long-term management of neurological and psychiatric conditions. By utilizing an advanced controlled-release matrix, this 250 mg dosage ensures a steady and consistent plasma concentration over a full 24-hour period. This minimizes the risk of breakthrough symptoms while significantly reducing dose-related side effects compared to traditional immediate-release tablets.
Key Composition
Each film-coated extended-release tablet contains:
- Divalproex Sodium (equivalent to Valproic Acid): 250 mg
Mechanism of Action
DICOVAL ER 250 targets multiple pathways to restore neurological stability:
- Enhancing GABA Levels: It elevates the activity of Gamma-Aminobutyric Acid (GABA)—the brain's primary "calming" neurotransmitter—to inhibit over-excited nerve signals.
- Sodium Channel Stabilization: It blocks voltage-gated sodium channels, preventing the rapid, repetitive firing of neurons that triggers seizures and migraine auras.
- Glutamate Inhibition: It reduces the effects of excitatory neurotransmitters that can lead to neuronal distress and mood instability.
The DICOVAL ER 250 Advantage
- Consistency: The ER delivery system prevents the "peaks and troughs" associated with standard medication, providing 24-hour protection.
- Improved Compliance: Ideally suited for patients requiring a lower initial dose or specific titration as part of a personalized treatment plan.
- Better Tolerability: Lower peak blood levels help minimize common side effects like nausea, dizziness, and tremors.
- Convenient Dosing: Facilitates a simplified regimen, reducing the pill burden for patients on chronic therapy.
Dosage & Administration
As prescribed by a physician. DICOVAL ER 250 should be swallowed whole and not crushed or chewed to maintain its extended-release profile. It is typically taken once or twice daily at the same time each day for optimal results.